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Since the 1984 landmark publication by Hertzer and
colleagues from the Cleveland Clinic, the co-existence of
coronary artery disease (CAD) in patients with peripheral
arterial disease (PAD) has been zealously embraced by the
medical establishment.1 In that widely quoted study, 1000
consecutive patients undergoing operations for PAD un-
derwent preoperative cardiac catheterizations whether or
not they had symptoms of CAD. The investigators reported
that only 8% of their patients (roughly divided into thirds—
aortic, infrainguinal, and carotid disease) had normal coro-
nary arteries, whereas approximately one third had severe-
correctable or severe-inoperable CAD. Complications of
CAD (principally myocardial infarctions [MIs], congestive
heart failure [CHF], unstable angina, and arrhythmias)
remain the major causes of morbidity and mortality in this
patient population.2-5
This study probably overestimates the prevalence of
CAD in vascular patients, in part because epidemiologic
studies have shown a decline in CAD in the general US
population.6-10 Approximately 25% of the reduction in the
death rate occurring during the past 30 years is largely
related to primary prevention and a better understanding of
the events leading to coronary deaths.11-13 These decreases
in the incidence of new atherosclerotic disease will be offset
by the aging of the so-called “baby boomer” population; it
is estimated that one fifth of our population will be 65
years old by the year 2030.
The reportedly high prevalence of CAD in vascular
patients has led to numerous evaluation and management
algorithms. Little unanimity of opinion exists, and ques-
tions remain, including: (1) What events define coronary
morbidity? (2) Which coronary artery lesions are most likely
to produce adverse perioperative cardiac outcomes? (This
question is of particular importance.) (3) Should the strat-
egy for cardiac evaluation and management depend on the
location of peripheral arterial atherosclerosis? (4) Is screen-
ing worthwhile, or should we assume that most vascular
patients have CAD? (5) How “bad” are the adverse cardiac
morbidity and mortality outcomes? (6) What is the safety
and efficacy of the evaluation of and revascularization for
CAD? (7) What is the role for perioperative “optimization”
of patients suspected to have CAD? (8) With studies cur-
rently underway, what are our present recommendations?
This review summarizes the available data and specu-
lates on current and future research.
DEFINING ADVERSE CARDIAC OUTCOMES-
WHAT EVENTS DETERMINE CORONARY
MORBIDITY?
Numerous adverse cardiac events have been evaluated
and considered to be “end points” in clinical reviews of
peripheral vascular operations, including: (1) unstable an-
gina pectoris, (2) congestive heart failure (CHF), (3) ar-
rhythmias, (4) myocardial ischemia (both overt and “si-
lent”), and both (5) non-fatal MI and (6) fatal MI.14 The
first 4 are relatively “soft” outcomes. Although unstable
angina is an acute coronary syndrome (ACS), it does not
routinely produce lasting damage. Its definition is variable,
ranging from a change in frequency of chest pain to unre-
lenting pain that is unresponsive to standard therapeutic
maneuvers. CHF may result from fluid overload, often
occurring after vascular procedures or after the use of a
narcotic agent as a primary anesthetic.15,16 Moreover, the
criteria required to confirm a diagnosis are often subjective
(jugular venous distention, dyspnea, rales, S3, chest radio-
graph findings, pedal or sacral edema, objective measure-
ment of decreased cardiac output—in variable combina-
tions). Arrhythmias may be brief, self-limiting,
hemodynamically benign, and caused by factors other than
cardiac disease, including hypoxia, drug toxicity, or meta-
bolic derangements. Myocardial ischemia occurs in 20% to
40% of patients; adverse events develop in 50% of pa-
tients.17-19 The importance of perioperative myocardial
ischemia detected by means of routine Holter monitoring
has been shown,20-25 although a recent report by Landes-
berg and associates indicated that during 11,132 patient-
hours of monitoring after surgery, 38 of 185 consecutive
patients had 66 transient ischemic events, but only 12
patients (6.5%) sustained perioperative MIs.19 In addition,
Kirwin and coworkers were unable to correlate silent myo-
cardial ischemia on preoperative continuous ambulatory
cardiogram (ECG; Holter) monitoring with perioperative
MIs.26
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Nonfatal and fatal MIs are the most important and
specific “hard” outcomes that determine cardiac morbidity.
The diagnosis of acute MI, as defined by the World Health
Organization (WHO) and recently revised by a Joint Eu-
ropean Society of Cardiology/American College of Cardi-
ology (ACC) committee, requires 2 of the these criteria: (1)
a history of prolonged typical chest pain; (2) evolutionary
changes on the ECG; (3) elevation of serial cardiac en-
zymes.27,28 Symptoms are atypical or absent postopera-
tively in as many as 75% of patients who objectively exhibit
MI, which is masked by residual anesthetic effects, analgesic
agents, competing somatic stimuli such as incisional pain,
etc.29-35 ECGs are difficult to interpret and often do not
exhibit classical ST-segment elevations or development of
MI-associated Q waves.36,37 (The principal method of
statistical analyses of these sorts of committee definitions
uses the BOGSAT technique—“Bunch of Guys Sitting
Around a Table” [personal communication: Jerry Gold-
stone, Case Western Reserve University, Cleveland,
Ohio].)
Traditional enzymes used as a means of determining
MIs (creatine phosphokinase [CK]) may be released from
skeletal muscle because of surgical trauma or ischemia/
reperfusion injuries, which mask the isoenzyme CK-MB
released from dying myocardial cells. Troponins (C, T, and
I) are normal muscle proteins involved in the calcium-
regulated, actin-myosin interactions.38,39 Troponin I and
T, but not C, exist as distinct cardiac-specific subtypes, and
both qualitative and quantitative assays on the basis of
antibodies to cardiac troponin T (cTnT) and I (cTnI) have
been developed and approved by the US Food and Drug
Administration (FDA) for use in the clinical diagnosis of
MI. To date, most investigations have used cTnT as a
means of determining the presence and extent of cardiac
ischemia, but there is cross-reactivity with skeletal muscle
troponin T.
In contrast, cTnI, found only in cardiac tissue, is 13
times more abundant in the myocardium than CK-MB. It is
not detectable in the blood of healthy individuals or in
patients with renal failure (as are CKMB and cTnT), and it
may remain elevated for 7 to 10 days after an episode of
myocardial necrosis.40,41 CK and CK-MB are released only
when this occurs. Elevation of cTnI has been shown to be
an independent mortality risk factor in patients with unsta-
ble angina; non-Q-wave MIs and higher levels correlate
with high mortality rates42-46 and new regional wall motion
abnormalities on echocardiography.47 Each increase of 1
ng per milliliter in cTnI is associated with a significant
increase (P  .03) in the risk ratio for death after adjust-
ment for baseline characteristics.48-50 Andrews and col-
leagues demonstrated that cTnI levels were accurate means
of detecting myocardial ischemia in patients undergoing
vascular surgery.51 The currently accepted definition of MI
(inapplicable to many earlier studies), recently formulated
by the European Society of Cardiology/ACC in a consen-
sus document, indicates its occurrence when cTnI levels are
3.1 ng/mL after prolonged ST-segment elevation.52,53
Although much prose has been devoted to the importance
of nTcI, ECG ST-segment changes are at least equally
important in diagnosing cardiac injury after vascular oper-
ations.54 Elliott M. Antman recently summarized decision-
making with cardiac troponin tests in the New England
Journal of Medicine (Jun 27, 2002).55
PATHOPHYSIOLOGY OF ACUTE CORONARY
EVENTS-WHICH CORONARY LESIONS ARE
MOST LIKELY TO PRODUCE ADVERSE
OUTCOMES?
Primary MIs in patients who are ambulatory are most
likely caused by stenoses 50% (ie, non-hemodynamically
significant lesions), in contrast to PAD, in which higher-
grade lesions are most likely to produce complications (eg,
transient ischemic attacks, strokes, lower-extremity isch-
emia, etc).56-74 Cardiac events result from disrupted ath-
erosclerotic plaques, which need not be stenotic to rupture
and cause occlusive thrombosis. The distribution of post-
operative MIs is not necessarily the same as hemodynami-
cally critical coronary artery lesions.75 “Unstable” plaques
have a large lipid core and a thin weakened fibrous cap
infiltrated by macrophages and other inflammatory cells
(Fig 1); these plaques are considered to be most vulnerable
to disruption. Cytokines and proteases involved in the
balance between synthesis and degradation of collagen and
elastin that determine the structural integrity of the plaque
cap play an important role.
There is great interest in the role of inflammation
within or surrounding the plaque as a precursor of rupture.
Unstable lesions may be especially prone to infection with
chlamydia, cytomegalovirus, or helicobacter that may con-
tribute to plaque instability or vulnerability. Evidence sup-
porting the role of inflammation includes the visible pres-
ence of inflammatory cells in and around the lesion,
activation of metalloproteinases near the plaque fissures,
and finding a variety of inflammatory mediators in and
around the lesion. Hence, C-reactive protein (a non-spe-
cific indicator of active inflammation) in the plasma is
important as a long-term predictor of MI risk.76-83 Aspi-
rin’s ability to reduce C-reactive protein levels and infarc-
tions likely relates to both its antiplatelet and anti-inflam-
matory actions.67,81,84 Inflammation within vulnerable
coronary artery plaques may cause acute events by promot-
ing rupture and erosion. Buffon and colleagues recently
measured the neutrophil myeloperoxidase content in the
cardiac and femoral circulations in patients with angina that
was stable, recurrent, or unstable.85 They reported wide-
spread activation of neutrophils across the coronary vascu-
lar bed in patients with unstable angina, regardless of the
location of the culprit stenosis, which challenges the con-
cept of a single vulnerable plaque in acute coronary syn-
dromes (Fig 2). There was significant correlation between
systemic levels of C-reactive protein and neutrophil myelo-
peroxidase content in blood from the great cardiac vein.
Thus, C-reactive protein levels and activated neutrophils
are markers of widespread inflammatory processes. This
possibility has important implications for research and ther-
apy and challenges the widely accepted hypothesis that a
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single vulnerable plaque is responsible for the development
of coronary instability, which questions the logic of percu-
taneous transluminal coronary angioplasty (PTCA)/stent-
ing or bypass grafting for a presumed “index” plaque.
Antiplatelet therapy may be even more effective in the big
picture.85-88
Recognizing the unstable or vulnerable coronary
artery plaque has led to “stabilizing” therapeutic ap-
proaches, such as administration of lipid-lowering med-
ications (gemfibrozil, HMG Co-A reductase inhibitors
[“statins”], niacin, etc), even in individuals with CAD
but without demonstrable hyperlipidemias.89-103 Sacks
et al showed that disruption of coronary artery plaques
can lead to neointimal proliferation, vasoconstriction,
and occlusive thrombosis.93,94,97,99,101,104 Pitt et al ran-
domized 341 patients with stable CAD to receive treat-
ment with atorvastatin versus revascularization.104 The
low-density lipoprotein level was maintained at 115
mg/dL of LDL versus percutaneous revascularization.
This data showed that, in patients with stable CAD who
are at low risk for myocardial infarction, aggressive lipid-
lowering is at least as effective as angioplasty and usual
care in reducing the incidence of ischemic events.105
Because plaques do not need to be greatly stenotic to
rupture and cause acute thrombosis, the Committee for
the Mechanisms Precipitating Acute Cardiac Events has
estimated that stenotic plaques are responsible for ap-
proximately one third of thrombotic events, although
they may serve as a marker for the number of non-
stenotic plaques present (ie, “atherosclerotic bur-
den”).75 At present, there are no validated invasive or
non-invasive methods for identifying plaques vulnerable
to disruption in patients, which casts doubt on the
relevance of current preoperative screening studies, be-
cause these tend to be a means of identifying hemody-
Fig 1. Line drawing of stable and unstable atherosclerotic plaques. Identification, intervention, or both for hemody-
namically significant coronary artery lesions may not provide secure protection against perioperative adverse cardiac
events after vascular surgery (see text for explanation). (Falk E, Fuster V. Angina pectoris and disease progression.
Circulation 1995;92:2058-65. Copyright © 1995 Massachusetts Medical Society. All rights reserved.)
Fig 2. Color electron micrography shows extraordinary infiltra-
tion of myeloperoxidase-laden neutrophils into a section of coro-
nary artery from a patient with unstable angina. Because this diffuse
process is not localized to a single vulnerable plaque, focused
therapy (eg, percutaneous transluminal coronary angioplasty or
coronary artery bypass grafting) may not be protective against
coronary events. Alternatively, anti-inflammatory (eg, antiplatelet
therapy), stabilization with anti-lipid treatments, and -blockers to
decrease myocardial oxygen consumption may be more beneficial
than mechanical approaches. (Buffon A, Fiasucci LM, Liusso G, et
al. Widespread coronary inflammation in unstable angina. N Engl
J Med 2002;347;5-12. Copyright © 2002 Massachusetts Medical
Society. All rights reserved.)
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namically significant lesions that may or may not be
unstable or vulnerable for producing acute coronary
syndromes.
Identifying unstable or vulnerable plaque provides im-
portant pathophysiologic and therapeutic information for
treating patients with CAD, whether or not they are under-
going non-cardiac operative procedures. Depre´ and col-
leagues in Belgium used directional coronary atherectomy
and histologic and biochemical analysis of extracted plaque
fragments to study coronary artery plaques. All plaque
fragments retrieved from patients with stable angina were
fibrous, whereas cellularity increased with unstable angina
in proportion to the severity of the plaque instability
score.106 This corroborates the hypothesis put forth by
Fuster and others that plaque thickness and stability is
relatively “protective” against acute coronary events (as
aforementioned).71,107,108 Depre´ concluded that the mor-
phologic pattern of coronary atherosclerotic lesions varies
at different stages of acute coronary syndromes; different
stages of angina correlate with an increasing prevalence of
these morphologic characteristics: thrombus, atheroma,
neovascularization, and cellular hyperplasia (ie, plaque
thickness).
It is clear that a well-done provocative test that pro-
duces normal results confers a high negative-predictive
value for perioperative cardiac problems. Virtually all avail-
able screening tests are means of assessing hemodynamic
abnormalities in cardiac perfusion. If hemodynamically sig-
nificant stenoses do not reliably produce cardiac events,
“positive” test results have a low positive-predictive value.
Prospective surveillance studies with screening ECGs and
enzyme data report perioperative myocardial ischemia rates
as high as 30% for ECG changes alone and 18% for those
with cTnI elevations.51 Landesberg et al reported a 32%
incidence of perioperative myocardial ischemia after sur-
gery.18 In 1996, a Journal of the American College of
Cardiology meta-analysis review article comparing intrave-
nous dipyridamole-thallium-201 imaging and dobutamine
echocardiography for risk stratification before surgery con-
cluded that cardiac event rates were low in patients without
a history of CAD (1% in 176 patients) compared with
patients with CAD and a normal or fixed-deficit pattern
(4.8% in 83 patients) or 1 thallium-201 redistribution
abnormalities (18.6% in 97 patients, P  .0001).109 Be-
cause of the diffuse nature of atherosclerosis, it is not
surprising that CAD occurs with great frequency, regard-
less of the location of peripheral arterial occlusive disease.
Most of the literature about cardiac morbidity has focused
on patients requiring aortic reconstructions for either an-
eurysmal or occlusive disease. Myocardial damage in these
patients was attributed to aortic crossclamping, declamping
hypotension, and fluid shifts associated with major abdom-
inal operations. However, investigators have consistently
shown strikingly high occurrence of early and late cardiac
morbidity in patients requiring infrainguinal arterial oper-
ations.
Hemodynamically positive test results may indicate a
large coronary artery atherosclerotic “burden,” thus war-
ranting concern for postoperative cardiac complications.
Thus, the index lesions identified with preoperative testing
may not be a accurate means of predicting the precise
myocardium at risk. The wide variety of available tests
suggests that, thus far, no one study is a means of reliably
predicting perioperative cardiac adverse consequences.
Acute MIs may have been caused by plaque disruption at
the site of hemodynamically insignificant coronary le-
sions.110,111 Mickley showed that the demonstration of
significant stenoses (50%) often leads to mechanical re-
vascularization, including PTCA or coronary artery bypass
grafting (CABG), but coronary angiography is not an ade-
quate means of predicting the location of the culprit plaque
that will subsequently produce acute MI.112 These studies
apply to vascular surgery patients who are found to have
relatively or completely asymptomatic CAD.
PREVALENCE OF ADVERSE CARDIAC EVENTS
IN VASCULAR PATIENTS-SHOULD STRATEGY
FOR CARDIAC EVALUATION AND
MANAGEMENT DEPEND ON LOCATION OF
PERIPHERAL ARTERIAL ATHEROSCLEROSIS?
The prevalence of CAD in PAD patients is widely
accepted,113-115 but the frequency of adverse cardiac out-
comes is controversial. In the Cleveland Clinic study, he-
modynamically significant CAD was demonstrated in 36%
of patients with abdominal aortic aneurysms, 28% of pa-
tients with lower-extremity ischemia, and 32% of patients
with extracranial carotid artery disease.115 This prevalence
is hard to dispute, but a comparison of morbidity rates
between studies is often misleading because the frequency
of cardiac complications depends on how vigorously the
diagnosis is pursued.116 On average, retrospective reviews
(with clinical criteria like the Cleveland Clinic studies)
report lower perioperative MI rates than series in which
data are gathered in a proscribed prospective fashion. We
have reviewed all major series reporting 100 or more pa-
tients, and the average MI rate after aortic, carotid, and
infrainguinal operations; the published MI rates were 2.2%
(7500 patients), 1.0% (28,000 patients), and 4% (6000
patients), respectively. According to our previously pub-
lished studies, early adverse cardiac outcomes occur at least
as frequently after infrainguinal procedures as aortic oper-
ations117; late events occur about twice as often in patients
requiring infrainguinal operations as in patients undergo-
ing aortic procedures (25% adverse cardiac events in pa-
tients requiring infrainguinal operations vs 8% in patients
requiring aortic procedures at 2-year follow-up; P 
.04).118 L’Italien and coworkers reported a 2-fold acute
increase in the early morbidity rate in infrainguinal proce-
dures compared with aortic procedures (13% vs 6%).119
Fewer postoperative events usually occur after carotid op-
erations; the reported MI rate after carotid endarterectomy
averages only 1.0% (see above).
In contrast, Ennix et al reported an operative mortality
rate of 18.2% in 77 patients undergoing carotid endarter-
ectomies without coronary revascularization, compared
with a mortality rate of only 3% in 135 patients undergoing
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either earlier coronary artery bypass grafting or simulta-
neous carotid endarterectomy and coronary artery bypass
grafting.1,120 Hertzer and Lees tracked 335 patients after
carotid endarterectomies who were observed 6 to 11 years
after surgery. MI caused 38.5% of the deaths that occurred
within 11 years, accounting for 60% of early deaths within
30 days of surgery, which occurred in only 1.8% of the
entire series. Although we have not performed a formal
meta-analysis on this information, we estimate the average
perioperative fatal/nonfatal MI rates associated with aortic,
infrainguinal and carotid surgery to be 2.2%, 4.0%, and
1.2%, respectively. These estimates are far lower than what
often appears in the literature. References for each series are
available to readers by accessing our online sources. Our
goal was to decipher true MI rates, a difficult feat for several
reasons. For example, many studies report “adverse cardiac
outcomes” rather than documented MI rates, whereas we
discuss the problems of CHF and arrhythmias in “hard”
outcome measures. In addition, although the literature
may contain instances of “improved results,” finding refer-
ences to patients who experience extraordinarily high MI
rates is less likely.
Review of the 41,500 patients having aortic, carotid,
and infrainguinal operations discussed previously indicates
several important trends: (1) the incidence of fatal/nonfatal
MI after carotid surgery is by far the lowest of common
vascular procedures; (2) the rate of MIs after aortic surgery
averages about 2%, and the values remain fairly stable
despite a plethora of strategies to avoid cardiac morbidity in
the past decade; and (3) fatal/nonfatal MI rates after in-
frainguinal surgery (acutely) average approximately 4%,
with a trend in decreasing rates in recent series, perhaps
suggesting the strength of our data from the 1990s. Over-
all, improvements may also be related to the more wide-
spread use of -blockers or anesthesia optimization.
PREOPERATIVE SCREENING TESTS-IS
IDENTIFICATION OF THE PATIENT AT HIGH
RISK FOR CORONARY ARTERY DISEASE
WORTHWHILE, OR IS IT PREFERABLE SIMPLY
TO ASSUME THAT MOST VASCULAR PATIENTS
HAVE SOME CORONARY ARTERY DISEASE?
As “outcomes research” comes of age, discussions of
preoperative screening tests dominate the literature. A re-
cent review article in the New England Journal of Medicine
summarizes these tests in patients with stable CAD.121 We
have also summarized the strengths and weaknesses of
many of these studies.122,123
The principal goals of preoperative identification of
patients at high risk for adverse cardiac outcomes are to: (1)
permit treatment of underlying CAD (eg, PTCA or
CABG), (2) use more intensive or “safer” anesthetic tech-
niques (eg, pulmonary artery pressure-monitoring cathe-
ters), (3) administer medications to decrease morbidity (eg,
beta blockers), or (4) change preoperative plans (eg, per-
forming axillobifemoral rather than direct aortic recon-
struction for aortic occlusive disease). These tests range
from completely noninvasive (eg, scoring systems), to min-
imally invasive (eg, echocardiographic estimation of ejec-
tion fraction), moderately invasive (eg, dipyridamole thal-
lium screening tests), and very invasive (eg, coronary
angiography), which underscores the absence of a consen-
sus for optimal risk stratification. Various clinical risk indi-
ces have been proposed.121,124-128,129-134 We and others
recently reviewed the literature on screening.123,135,136
Additional recommendations for preoperative tests
abound, as this abbreviated list describes: (1) exercise tread-
mill testing (ETT; eg, the “Bruce Protocol”, which many
vascular patients cannot undergo because of claudication,
congestive heart disease, chronic lung disease, etc)137-141;
(2) ambulatory electrocardiography (Holter monitor-
ing)14,24,25,117,142,143; (3) radionuclide ventriculography
(RNVG)144-146; (4) dipyridamole thallium scintigraphy
(DTS)32,147-156; and (5) dobutamine or sestamibi stress
echocardiography.147,148,150,153 Numerous studies pre-
dicting the occurrence of adverse cardiac outcomes have
also appeared (eg, a comparison of clinical examination,
exercise testing, dobutamine stress echocardiography, and
coronary arteriography by Therre et al).157
Most authorities agree that coronary angiography pro-
vides precise anatomic assessment of the status of CAD, but
it is difficult to justify its routine use unless the patient’s
symptoms warrant revascularization on their own merits.
Using decision analysis techniques, Mason and coworkers
from Stanford University compared 3 strategies for dealing
with CAD.158 They found that vascular surgery without
preoperative coronary angiography generally leads to better
outcomes and that that procedure should be reserved for
patients whose estimated mortality rate with surgery is
substantially higher than average. Glance compared the
cost-effectiveness of 4 preoperative screening strategies on
the basis of mortality rates, morbidity rates, and cost data
from a literature review,159 concluding that selective
screening before vascular surgery may improve 5-year sur-
vival rates and be cost-effective, especially when compared
with routine angiography. The incremental cost-effective-
ness ratio for selective screening was significantly lower
than for routine angiography ($44,800/years of life saved
[YLS] vs $93,300/YLS; P  .02). Other studies have
described similar comparisons.160
As aforementioned, these tests rely heavily on the de-
velopment of hemodynamically related symptoms (gener-
ally caused by hypoperfusion) or demonstration of a hemo-
dynamically significant stenosis. Because we are unable to
identify the most vulnerable and unstable plaques, these
tests have failed as a means of reliably predicting postoper-
ative myocardial events. Normal test results do correlate
with absence of events, most likely because of a lesser
atherosclerotic-CAD burden; this results in the good “neg-
ative-predictive value” of many studies, but the failure to
predict adverse cardiac outcomes accurately. Poldermans’
study of preoperative dobutamine stress echocardiography
(DSE) in patients who subsequently died of acute MI and
underwent autopsy by a pathologist unaware of the DSE
results found a relatively poor correlation of the anatomic
location of the infarction; in 50% of patients, the MI
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extended beyond the ischemic territory assessed by means
of DSE.161 Poldermans concluded that perioperative med-
ical therapy should be aimed at coronary plaque stabiliza-
tion.
In 1996 and 2002, the ACC and the American Heart
Association (AHA) appointed a task force to develop
guidelines for perioperative cardiovascular evaluation for
non-cardiac surgery. With the exception of Dr Norman
Hertzer, a member of the 1996 committee, surgeons gen-
erally have been under-represented in this task force. The
guidelines are an attempt to present “everything you ever
wanted to know about cardiac disease in vascular patients;”
however, the lack of surgical input and the complexity of
the document limit its usefulness. Fig 3, online only is an
algorithm that summarizes the ACC/AHA guidelines. Al-
though there is much useful information in the publication,
it is overwhelmingly complex.
Despite this, numerous publications have shown the
usefulness of these guidelines. Samain et al retrospectively
applied the guidelines to a group of 133 patients undergo-
ing aortic surgery,100 concluding that had the investigators
used the guidelines, at least 1 cardiac-related death could
Fig 3. Algorithm recommended by the American College of Cardiology and American Heart Association. Eagle KA,
Berger PB, Calkins H, et al. ACC/AHA Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac
Surgery. American College of Cardiology/American Heart Association Practice Guidelines 2002;1-58.
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have been avoided. This is pure speculation. Farid and
colleagues162 at the Cleveland Clinic found abnormal test
results in 27 of 181 patients scheduled for major surgery; 2
patients declined treatment, 8 patients had primary medical
management, and 17 patients had cardiac catheterization
with a variety of findings (including 2 “normal” results).
Only 15% (27/180) of the patients with indications for a
stress test had test results that were positive for cardiac
disease; even fewer patients had any alteration of the peri-
operative period. On the basis of this study, the guidelines
appear to have very little effect on perioperative outcome.
We await the results of a recently completed prospective
evaluation from the University of Michigan on implement-
ing the ACC/AHA guidelines for preoperative cardiac risk
assessment before aortic surgery (personal communica-
tion).
PERIOPERATIVE ADVERSE
OUTCOMES—HOW “BAD” IS “BAD?”
Much of what is known about the incidence of acute
MI and fatal coronary heart disease comes from isolated
community surveillance studies,113,163-165 cohort studies
of cardiovascular disease,166,167 or managed-care program
studies.168 We already discussed the apparent decrease in
deaths caused by CAD in the general US popula-
tion.7,10,169
In patients after surgery, adverse outcomes of transmu-
ral, Q-wave MIs are well documented. Mangano et al
indicated that of 25 million patients who undergo non-
cardiac operations in the United States each year, approxi-
mately 3 million are at risk of having CAD; approximately
50,000 of these patients have a perioperative MI.14 More
than half of the 40,000 annual postoperative deaths are
caused by transmural MIs.5 In reviewing several thousand
procedures, Hertzer found that cardiac complications were
responsible for approximately half of all perioperative
deaths; fatal events were nearly 5 times more likely to occur
when standard preoperative indications of CAD were
present.114 Sprung and colleagues analyzed 6948 opera-
tions and found 107 patients with postoperative transmural
MIs.170 The 20.6% overall in-hospital mortality rate was
highest on postoperative day 0. Similarly, Badner et al
reported a 17% post-MI mortality rate after non-cardiac
surgery.171 Although these rates are better than those
reported in older series (presumably because of improved
anesthetic care, -blockers, etc), a death rate from MI of
almost 1 in 5 is startlingly high.
Furthermore, the late (5-year) mortality rate for vascu-
lar patients suspected of having CAD is twice that for
patients not suspected of having it (approximately 40% vs
20%).14 We reported an adverse cardiac outcome risk of
25% in patients who underwent infrainguinal bypass graft-
ing in a short 2-year follow-up.118 In Wilson’s recent
editorial, when Rene´ Leriche´ termed vascular intervention
the “surgery of ruins,” he attributed the shortened survival
rate to systemic atherosclerosis.172 Wilson went on to say,
“As a rule of thumb, one can estimate a mortality rate of
approximately 5% per year in patients who have undergone
operation for arterial occlusive disease at any site.” If any-
thing, this estimate is probably low.
Some have questioned the clinical importance of non-
Q-wave MIs (ie, “chemical” MIs) in vascular surgery pa-
tients. Yeager and colleagues observed 8 of 31 patients who
sustained a perioperative MI with “chemical MIs” in which
enzyme elevation was the sole indicator of postoperative
MI.173 At a mean follow-up period of 27.7 months, the
survival rate for patients with nonfatal perioperative MI at 1
and 4 years was 80% and 51%, respectively, which did not
differ significantly from that of control patients (90% and
60%, respectively; P  .05) Although, these investigators
concluded, “a perioperative ’chemical MI’ may not be a
clinically significant clinical event, patients surviving nonfa-
tal perioperative MIs after peripheral vascular surgery did
have a higher incidence of subsequent adverse cardiac
events and coronary artery revascularization.” McFalls et al
reported that, even in patients with perioperative transmu-
ral MIs, non-fatal perioperative MI was only a marginally
significant independent predictor of the 1-year mortality
rate (P  .06), whereas the extent of vascular disease at
presentation was a more important determinant of long-
term survival.174
Such optimism about the relative benign outcomes
after “chemical” MIs is not supported by the literature.
More than half of all acute MIs in the United States that
occur in patients who are ambulatory are non-Q-wave MIs,
and this proportion is rising.164,170,175 Several investiga-
tions reported higher rates of both early and late ischemic
complications, such as reinfarction and post-infarction an-
gina, presumably because of the presence of viable but
jeopardized myocardium within the perfusion zone of the
artery responsible for the infarction.175-186 The best man-
agement approach to non-Q-wave MIs is controversial.
The 1987 ACC/AHA guidelines recommended routine
coronary arteriography for all patients after non-Q-wave
infarction113; newer guidelines no longer endorse this ap-
proach.102,187 To determine the optimal treatment strat-
egy for patients with non-Q-wave MIs, Boden et al per-
formed a multicenter prospective randomized trial
comparing invasive management (routine coronary an-
giography followed by myocardial revascularization) with
conservative management (medical therapy and non-inva-
sive testing).175 The VANQWISH (Veterans Affairs Non-
Q-Wave Infarction Strategies in Hospital) trial randomized
920 patients to 1 of the 2 strategies. A substantial 28% of
cardiac events occurred during the follow-up period of 12
to 44 months, but the overall mortality rate did not differ
significantly between groups. The investigators recom-
mended a conservative, ischemia-guided initial approach.
Although this study may be criticized for potential inappli-
cability to women, it cannot be said that patients cared for
in Veterans Health Administration (VHA) hospitals re-
ceived care of poorer quality than patients cared for else-
where. Petersen et al compared 2486 veterans discharged
from 81 VHA hospitals and 29,249 Medicare patients
discharged from non-VHA hospitals and found no differ-
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ence in mortality rates, even though VHA patients had
more coexisting conditions.146
SAFETY AND EFFICACY OF EVALUATION AND
REVASCULARIZATION FOR CORONARY
ARTERY DISEASE-IS THERE A “DOWNSIDE”
TO EXTENSIVE EXPLORATION/TREATMENT
FOR CORONARY ARTERY DISEASE?
We recently performed a retrospective analysis of our
experience with extended cardiac evaluations and interven-
tions before vascular surgery at the Denver Veterans Ad-
ministration Medical Center (VAMC).188 These evalua-
tions, which included standard screening studies and
special tests such as echocardiography, radionuclide ven-
triculography, dipyridamole thallium scintigraphy, and car-
diac catheterization, were performed in 42 patients. Nine
patients (21%) underwent PTCA, and 7 patients (17%)
underwent CABG. Unfavorable outcomes occurred in one
third of patients who were subjected to an extensive preop-
erative assessment of risk in a 1-year period (Table I, online
only). One fifth of the patients (8 patients) elected not to
undergo the vascular procedures indicated. Most of these
patients (7 of 8) had potentially life-threatening abdominal
aortic aneurysms. Multiple reasons were cited for refusal, to
the effect of “enough is enough.” No difference in cardiac
morbidity rates appeared between the patients who had
extensive evaluations/interventions and the patients who
did not (2.4% vs 2.9%; P  not significant). Patients refus-
ing vascular surgery were of particular interest; in the recent
ACC/AHA guidelines implementation review by Farid et
al,162 3 of 27 patients (11%) who met ACC/AHA criteria
either refused further treatment or never underwent the
originally planned non-cardiac operations. Although these
publications are relatively small, retrospective series and the
VAMC study did not have a strict protocol for determining
operative cardiac risk. We are concerned about the dearth
of benefits from extensive CAD searches.
Controversy about what to do when severe, correctable
CAD is identified also remains. Advocates of coronary revas-
cularization before peripheral vascular operations contend
that it both enhances the safety of the procedure itself and
potentially prolongs life expectancy. We discussed the report
by Ennix et al, in which prophylactic CABG markedly
improved long-term survival rates after carotid endarterec-
tomies.120 Similar results were reported for patients who
underwent PAD operations in other locations.115,189-192
Many reports describe substantial numbers of patients who
did very well after coronary revascularization, but they pertain
to studies that were neither randomized nor prospective.
We urge caution in applying coronary revascularization
before PAD surgery. Morbidity and mortality rates of
CABG and PTCA in elderly patients with PAD are substan-
tial. Cutler and Leppo examined 116 patients scheduled for
operations with dipyridamole-thallium scintigraphy and re-
ferred 7 patients (6%) for CABG. One patient (14%) died
after CABG; another died awaiting the procedure
(14%).193 No operative deaths occurred in the subsequent
106 operations; thus, the 2 deaths that occurred (1.7% of
total) were directly related to the screening. A policy of
prophylactic myocardial revascularization at the University
of Iowa led to CABG procedures in 15 patients, with a
mortality rate of 6.7% and postoperative complication rate
of 20%.194,195 Mesh and colleagues reported 3.6 times
higher morbidity rates (39.7%) in patients with PAD who
underwent CABG than patients without PAD (16.7%).194
Often, the recovery from this major morbidity either pre-
cluded or substantially delayed the surgery for which the
evaluation was undertaken. Even PTCA in patients with
PAD carries higher morbidity and mortality rates than it
does in patients without PAD.196,197 The increased long-
term survival rate in patients with CAD treated with coro-
nary revascularization as proven by means of the CASS
(Coronary Artery Surgery Study) trial may not apply to
older patients with PAD, a strong, independent predictor
of long-term mortality in patients with stable CAD. In
addition, the CASS patients all had significant symptoms,
whereas that may not be true for the patient with PAD
whose CAD is discovered by means of provocative testing
(ie, it may be unfair to extrapolate the CASS results to the
PAD population).198-200
To date, there are no prospective randomized compar-
isons between “aggressive” cardiac management and best
“conservative” medical care. Massie et al examined the
results of coronary revascularization in patients versus con-
trol subjects,201 observing ischemic responses to dipyrid-
amole scans in 297 patients, of whom 70 underwent cardiac
catheterization and 25 underwent coronary revasculariza-
tion. No difference in adverse outcomes occurred between
the coronary angiography group and 44% of the control
group. Patients who underwent coronary angiography and
were considered for cardiac revascularization had fewer
cardiac events with a subsequent vascular operation than
did the control subjects. However, any possible benefit
from invasive cardiac evaluation was offset by 3 deaths and
2 MIs that complicated the cardiac evaluation. There was
no significant difference in the rates of perioperative non-
fatal MI (13% vs 0%), fatal MI (4% vs 3%), late non-fatal MI
(16% vs 19%), or late cardiac death (10% vs 13%). In
summary, the risks of extended cardiac evaluation and
treatment did not produce any improvement in either the
perioperative or long-term survival rate. The authors con-
cluded that for most vascular surgery patients who have a
positive results on a dipyridamole-thallium scan, coronary
angiography does not provide additional useful informa-
tion or benefit.
BEST MEDICAL CARE-WHAT ARE THE ROLES
FOR PERIOPERATIVE “OPTIMIZATION” OF
PATIENTS SUSPECTED TO HAVE CORONARY
ARTERY DISEASE, INCLUDING THE USE OF
-BLOCKERS?
Optimizing a vascular patient’s volume status by means
of perioperative use of pulmonary artery catheters would
seem to enhance the safety of surgery. Surprisingly, neither
retrospective nor prospective trials have convincingly indi-
cated this. Since 1980, reports have described attempts at
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maintenance of optimal cardiac performance to improve
results of vascular (particularly aortic) surgery. Whittemore
and associates suggested that this was responsible for the
low perioperative mortality rate and improved late survival
rate in their patients, but the study was retrospective and
based on historical control subjects.202 More recent ran-
domized, controlled trials of pulmonary artery catheters
generally failed to improve outcomes. In 1997, Bender et al
randomized 104 consecutive patients having major opera-
tions to a pulmonary artery catheter versus placement of a
catheter “only if clinically indicated” (introducing potential
bias into this study).203 Except for a discrepancy in the
amounts of fluids administered, there were no significant
differences in outcomes or surgical intensive care unit
length-of-stay, which suggested no benefit of routine pul-
monary artery catheters in elective surgery patients. In
1998, Valentine and colleagues performed a truly random-
ized catheter trial.204 One hundred twenty patients under-
going elective aortic surgery were randomized to place-
ment of pulmonary artery catheters (n 60) or the control
group (intravenous hydration on the ward; n 60). These
investigators found no significant differences in the rates of
cardiac morbidity, renal insufficiency, of pulmonary events
or in the length of intensive care unit stay or length of
hospital stay between groups, and they concluded that there
was no benefit to routine catheter use. A recent meta-analysis
of routine perioperative pulmonary artery catheterization in-
dicated no effect on the rate of complications.205
Although in some of the aforementioned studies pa-
tients had pulmonary artery catheters placed while they
were in the intensive care unit the day before surgery, the
studies variably attempted to “optimize” the cardiac func-
tion of the patients involved. There is even more contro-
versy with this. At least 10 studies have addressed periop-
erative homodynamic optimization to improve outcomes
after vascular surgery, but most have been retrospective
reviews with historical controls and contradictory find-
ings.202,206-211 Four prospective, randomized controlled
trials of preoperative hemodynamic optimization of cardiac
and volume status in vascular surgery patients showed no
benefit, even when the goals of maintaining optimal arterial
and venous oxygen saturations were achieved.204,212-214
One “positive” randomized, prospective study of the effect
of deliberate perioperative increase of oxygen delivery on
mortality rates in high-risk patients with dopexamine hy-
drochloride showed improved outcomes, but this study
was not limited to vascular surgery operations.215 Thus,
most randomized, prospective trials have failed to show
significant benefits, and the costs to perform this routinely
would be enormous.
There have been few reports on the efficacy of admin-
istering theoretically beneficial medications to prevent car-
diac complications. For example, prophylactic nitroglycerin
infusion during non-cardiac surgery does not reduce peri-
operative ischemia, as shown in a prospective, randomized
study from Columbia University.216 Another rather im-
practical study examined the efficacy of a small oral dose of
clonidine in patients; although this drug was beneficial, the
absorption of an oral agent is unpredictable in vascular
surgery, and the work has not been confirmed by other
studies 6 years later.217 Finally, mivazerol, a drug with
alpha2-agonist properties (the “active” counterpart of a
-Blocker) was evaluated in a randomized, blinded, pro-
spective study of 1897 patients with CAD undergoing
non-cardiac surgery (48% vascular surgery), with no alter-
ation in the rates of MI or cardiac death.218 Studies of this
agent in vascular patients in the United States have been
discontinued.
In contrast to the absence of efficacy of these drugs, it is
now well accepted that -blockade efficaciously reduces
both short- and long-term cardiac morbidity and mortality
rates. Selzman and colleagues recently wrote a review arti-
cle of -adrenergic blockade as prophylaxis against periop-
erative cardiovascular morbidity and mortality219; it re-
views the history of -adrenergic blockade and summarizes
the pathophysiology of the mechanisms of action and data
supporting its use in virtually all vascular patients. This is
certainly not a new concept, although its popularity surged
only after recent prospective trials proved the efficacy.
Neurohormonal stress in surgery is at least in part related to
adrenal cortical stimulation with catecholamine release, one
of the links to perioperative myocardial ischemia associated
with vascular and other serious operations.220,221 Cat-
echolamines increase each of the 4 major determinants of
myocardial oxygen consumption (heart rate, preload, after-
load, and contractility).222 As early as 1982, Smulyan et al
recommended continuous propranolol infusion after ab-
dominal surgery.223 Yeager and coworkers from OHSU
reported reduction in perioperative MIs after vascular sur-
gery with -blockade.134 This work and subsequent non-
randomized studies led to 5 controlled, randomized, pro-
spective trials of perioperative blockade in patients (mostly
vascular) with known or probable coexistent CAD. These
studies are described in Table II, online only; all show a
decrease in acute or chronic cardiac morbidity and mortal-
ity with -blockade.224-229 In summary, acute periopera-
tive ischemic events, MIs, cardiac death, overall mortality,
and adverse cardiac events generally decrease in frequency
with the administration of -blockers.230 The advanta-
geous effects relate to the decreased myocardial oxygen
consumption they produce, as illustrated in Fig 4, which
summarizes the methods by which myocardial oxygenation
may be minimized.222,230 Moreover, administration of
-blockers in the perioperative period is both safe and
effective.231
CURRENT RECOMMENDATIONS-UNTIL
PROSPECTIVE STUDIES CURRENTLY
UNDERWAY ARE COMPLETED, WHAT ARE
OUR RECOMMENDATIONS FOR OPTIMAL
TREATMENT OF THE VASCULAR PATIENT
WITH CORONARY ARTERY DISEASE?
This review is replete with disclaimers about retrospec-
tive studies, absence of control data, and a notable absence
of level I data to guide treatment protocols.105 Currently
underway is a randomized prospective multicenter trial
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that will provide extremely important information about
optimal management. The protocol has been approved
and funded by the Veterans Affairs (VA) Cooperative
Studies Program (CSP) section; Mcfalls et al described a
complete protocol.174 Fig 5 summarizes the details of
randomization and algorithm of the study, which is titled
CARP (Coronary Artery Revascularization Prophylaxis).
A sample size of 559 randomized patients will provide
90% power to detect a difference in 3.5-year survival
rates of 75% versus 85%. By allowing for 10% of the
patients to drop out after randomization, the final target
sample size is 620 patients, which will be gathered at 18
high-quality VAMCs. As in every VA study, the results
will suffer from a lack of women, and recruitment has
been difficult thus far. Nevertheless, the study is pro-
ceeding remarkably well, and we are about halfway to
completion. Only prospective randomization of compa-
rable patients will provide the answer to whether coro-
nary evaluation, revascularization, or both before elec-
tive vascular surgery enhances the safety of vascular
surgery, prolongs the life of our patients, or both.
Until these results are available, we recommend keep-
ing things simple. Rather than follow the ACC/AHA
guidelines, we assume most of our vascular patients have at
least some degree of CAD. Because -blockade is clearly
effective in decreasing cardiac morbidity, optimization of
anesthesia and the use of -blockers effectively decrease
cardiac morbidity (as aforementioned). Fig 6 describes our
current recommendations. Many “boxes” are identical (ie,
operate, but assume most patients have some degree of
CAD; use -blockers in virtually all patients; and optimize
the rate/pressure product in anesthesia). We avoid provoc-
ative tests, coronary revascularization, or both, except in
unusual cases. When patients have severe CAD, consider-
Fig 4. Factors that play a role in myocardial oxygen consumption.
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ation is given to modifying the planned operation or using
conservative management.
Unfortunately, because CARP is a VA study with the
disclaimers associated with most such investigations, it is
likely that some controversy about optimal manage-
ment strategies will persist. Fleisher and Eagle recently
wrote a clinical practice guideline that concludes, “In
high-risk patients scheduled to undergo non-cardiac
surgery, coronary artery bypass grafting and percutane-
ous coronary revascularization are appropriate if they
are indicated independently of the need for non-cardiac
surgery.”232 We agree with this statement, as we do
with K.E. Raby’s editorial that concludes, “Is preop-
erative cardiac testing necessary among vascular
patients? Based on the above body of evidence, the
answer for most patients appears to be: No.”233
Bodenheimer has opined, “Otherwise, the tests should
be skipped and the patient cleared [for vascular
surgery].”234 We also agree with the title of Itani, Miller,
Guinn, and Jones’ article: “Preoperative cardiac evalua-
tion is unnecessary in most patients undergoing vascular
operations.”235 Finally, we agree with Goldman’s
editorial in which he concludes, “The bad news is we
still do not have all the answers. The good news is that
approaches to the treatment of a cardiac patient
undergoing non-cardiac surgery are increasingly being
driven by data, including data from randomized clinical
trials.”236
Fig 5. Algorithm of the CARP study (Coronary Artery Revascularization Prophylaxis), a Department of Veterans
Affairs-sponsored study that is a randomized prospective multicenter trial to answer the hypothesis that coronary artery
evaluation and revascularization will enhance the acute safety of peripheral arterial operations and increase long-term
survival. AAA, Abdominal aortic aneurysm; LVEF, left ventricular ejection fraction; LV, left ventricular.
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Table I, online only. Adverse outcomes in 16 of 42
patients undergoing extended cardiac evaluations before
major vascular surgery in a 1-year period at Denver
Veterans Affairs Medical Center
Complication Number of patients
Refused vascular surgery for which
cardiac evaluation was undertaken
8
Limb loss caused by delay in vascular
surgery during cardiac evaluation
2
Post-angiogram prosthetic graft infection
requiring graft removal/revision
1
Femoral artery pseudoaneurysm
requiring surgical repair
2
Sternal wound infection after CABG 1
Contrast-induced renal failure requiring
hemodialysis
1
Anoxic brain injury after CABG 1
Total 16 (38%)
CABG, Coronary artery bypass grafting.
From Krupski WC, Nehler MR, Whitehill TA, et al. Negative impact of
cardiac evaluation before vascular surgery. Vascular Medicine 2000;5:3-9.
Table II, online only. Controlled, randomized trials of perioperative -blockade (references and details listed in text)
Source Year N Drug Follow-up
Results
Control -blockers
Stone 1988 128 Control  39 Intraoperative 28% ischemia 2% ischemia
Labetalol  29
Atenolol  30
Oxprenolol  30 P  .001
Mangano 1996 200 Control  101 2 years 21% mortality 10% mortality
Atenolol  99 P  .019
Poldermans 1999 112 Control  53 30 days 17% cardiac death 3.4% cardiac death
Bisoprolol  59 P  .02
Raby 1999 26 Control  11 48 hours 73% persistent ischemia 33% persistent ischemia
Esmolol  15 P  .05
Urban 2000 107 Control  55 48 hours 15% ischemia
6% MI
6% ischemia
2% MIEsmolol  52
16% cardiac morbidity 11% cardiac morbidity
P  NS
Poldermans 2001 101 Control  44 2 years 32% cardiac events 12% cardiac events
Bisoprolol  57 P  .025
MI, Myocardial infarction; NS, not significant.
